Posted by Michael Wonder on 10 Apr 2025
Arcturus Therapeutics receives US FDA fast track designation for the STARR mRNA vaccine candidate ARCT-2304 for pandemic influenza A virus H5N1
10 April 2025 - Arcturus Therapeutics today announced that the US FDA has granted fast track designation for the self-amplifying mRNA vaccine candidate, ARCT-2304, designed for active immunisation to protect against disease caused by influenza A H5N1 subtype contained in the vaccine.
The Phase 1 clinical study initiated in November 2024.
